In 1956 Raventós reported an investigation of the pharmacologic behavior of a fluorinated hydrocarbon (2 bromo-2 chloro-1, 1, 1-trifluoroethane) which was found to be a potent inhalation anesthetic.1 The first clinical trials reported by Johnstone,2 Bryce-Smith, and O'Brien3 were quickly followed by further favorable reports.4-8 Since then this agent, halothane (Fluothane), has been both enthusiastically received as a clinical anesthetic and subjected to extensive laboratory and clinical investigation.9 Although one of the advantages of halothane is its nonflammability, inhalation anesthetic agents with which it has been commonly compared clinically are ether and cyclopropane, both of which are flammable and explosive, thereby limiting their comparable use under some conditions. Since their physical characteristics are quite different from halothane, dissimilar means of administration are usually used. Pharmacologic effects are also quite diverse. Chloroform, on the other hand, is a most logical agent for clinical comparison with
McREYNOLDS EC, THOROGOOD A, MORRIS LE. Clinical Comparison of Halothane (Fluothane) and Chloroform. Arch Surg. 1963;86(4):633–640. doi:10.1001/archsurg.1963.01310100117018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: